Articles tagged with Positron Emission Tomography
A new brain imaging study led by Weill Cornell Medicine researchers found that estrogen receptors in the brain increase with age during menopause, affecting cognitive and mood symptoms. The study pioneers PET imaging as a tool to track estrogen activity in the brain, revealing potential predictors of common menopause-related issues.
A new ultra-low dose imaging method with long axial field-of-view PET scanners can generate quantitative PET images without the need for accompanying CT scans, reducing radiation exposure to patients. The technique reduces the total effective dose by approximately 50 times lower than the standard PET dose.
The EXPLORER PET scanner provides images of the body in minutes with higher quality and less radiation than traditional scanners. The study found that lung tumors benefit from a dual-blood supply effect, which is more pronounced than in normal lung tissue.
The NeuroEXPLORER PET scanner offers exceptional brain PET images with ultra-high sensitivity and resolution, showcasing focal uptake in specific brain nuclei. This technology has the potential to spur advances in treating conditions like Alzheimer's disease, Parkinson's disease, and mental illnesses.
Research suggests that using hearing aids can help mitigate the acceleration of brain metabolism decline in individuals with mild cognitive impairment. The study found significant annual metabolic decline in frontal cortical regions among those with untreated hearing loss, whereas those with treated hearing aids experienced no such dec...
A novel imaging approach, Ga-DOTATATE PET/CT, offers enhanced sensitivity and specificity for detecting residual/recurrent tumors in patients with head and neck paragangliomas. This method improves the differentiation between tumor and scar tissue post-surgery.
Carolyn J. Anderson has made significant contributions to the development of radiometal-based agents for diagnostic imaging and targeted radionuclide therapy of cancer, a field known as 'theranostics.' Her work led to the FDA approval of Lu-177 DOTATATE for treating neuroendocrine tumors.
A multi-center study found that healthy older adults with beta-amyloid deposits showed significantly less training improvement in cognitive tasks. However, individuals without amyloid deposits demonstrated better cognitive plasticity and training effectiveness.
Researchers developed a novel radiotracer to detect Claudin18.2 in gastrointestinal cancers, allowing for early diagnosis and targeted therapy optimization. The radiotracer enables whole-body PET imaging within one day, increasing compliance and reducing radiation exposure.
A new PET imaging biomarker, Gal-1, has been identified to predict the tumor responses before starting immune checkpoint blockade therapy. This enables targeted interventions and improves patient outcomes by facilitating patient stratification and optimizing immunotherapy.
Researchers developed a Pix-2-Pix GAN model to correct PSMA PET/CT images, improving image quality and quantitative markers. The AI-generated images show high correlation with original images and potential for reducing CT scans without compromising image quality.
A new supplement to The Journal of Nuclear Medicine highlights China's significant advances in research and development, including long-field PET scanners and innovative theranostic concepts. The supplement aims to inform international collaborations and multicenter studies, featuring top experts in molecular imaging and theranostics.
A novel investigational PET imaging agent, <sup> 68 </sup> Ga-DPI-4452 (Debio 0328), has been shown to provide rapid and accurate visualization of lesions in clear cell renal cell cancer patients. The agent offers a superior alternative to standard CT imaging and could potentially be used as part of a theranostic pair.
A new study from Brigham and Women's Hospital suggests that PET brain scans can detect hidden inflammation in MS patients who are being treated with highly-effective treatments. The findings indicate that smoldering inflammation may linger in patients, driving disease progression and symptoms.
Researchers found that individuals from certain racial and ethnic groups are less likely to be eligible for Alzheimer's disease clinical trials due to lower amyloid levels at early stages of the disease. Amyloid buildup in the brain varies across different populations, contributing to underrepresentation in clinical trials.
Researchers developed a novel theranostic platform that combines PET imaging and therapeutic radionuclides to detect and treat ovarian cancer. The system uses the huAR9.6 antibody to target the MUC16 protein, showing promise for improved patient survival rates.
Researchers developed a novel PET tracer that can map fructose metabolism, differentiating diseased tissues from healthy ones. This non-invasive technique has the potential to detect diseases such as stroke, brain metastases, and heart attacks more sensitively.
A study published by the University of Florida suggests a connection between elevated amyloid blood levels and subtle brain microstructural changes in individuals without dementia. Researchers used diffusion MRI to detect free-water in the brain, revealing associations with structural abnormalities even when PET scans were negative.
Researchers identify a promising prognostic biomarker for lung cancer using circulating tumor DNA-based minimal residual disease detection. The study found that this method can effectively guide treatment decisions and predict recurrence risk, potentially modifying the lung cancer treatment paradigm.
A novel imaging technique, low-dose positron emission mammography (PEM), shows promise in transforming breast cancer detection by providing high sensitivity and low false positive rates. PEM could potentially decrease healthcare costs and reduce unnecessary procedures for patients with dense breasts.
A novel PET imaging technique can detect active inflammation in the body before clinical symptoms arise, using a PET tracer that binds to proteins present on activated immune cells. This makes it easier for physicians to correctly diagnose and treat patients with rheumatoid arthritis.
A team of scientists from the Beckman Institute has received a $3 million grant to develop diagnostic tools and imaging agents for the early detection of Alzheimer's disease. They will use a combination of PET and MRI scans to target smaller beta-amyloid peptides and other signs of neuroinflammation and oxidative stress.
Researchers developed a new imaging technique to visualize the tumor microenvironment of glioblastoma, revealing insights into its pathology. The technique uses PET imaging with Carbon-11 acetate, tracking reactive astrocytes and distinguishing them from tumor cells.
Researchers successfully reduced bladder tumor size by 90% in mice using nanorobots propelled by urea. The nanomachines deliver a radioisotope to the tumour, attacking it with precision and efficiency. This breakthrough could lead to more effective bladder cancer treatments and reduced hospitalization costs.
A novel PET imaging agent has been found to effectively identify medullary thyroid cancer (MTC) in preclinical and clinical studies. The compound demonstrates favorable tumor uptake and improved activity clearance from off-target tissues, potentially enhancing lesion detection and enabling targeted MTC radioligand therapy.
Researchers have successfully used mRNA technology to correct a rare genetic disease in mice, demonstrating its potential therapeutic use. The treatment corrected the lethal consequences of the disease and restored glutathione metabolism.
The Society of Nuclear Medicine and Molecular Imaging has published a new procedure standard/practice guideline for estrogen receptor imaging of breast cancer patients using FES PET. The guideline aims to promote the appropriate use of FES PET and enhance research, providing advantages in assessing tumor ER expression and predicting re...
A new framework has been established for standardized imaging of diffuse gliomas using amino acid PET, enabling the evaluation of treatment success and improving therapies. The RANO group has developed criteria that enable reliable imaging of tumor activity and extent.
A new PET imaging tracer has been developed to detect a common cancer gene mutation with high accuracy. The tracer targets the KRAS G12C protein, allowing for early identification of patients who can benefit from targeted therapy.
A new study found that Ga-68 FAPI PET imaging can effectively detect and stage pancreatic cancer, outperforming existing methods. The imaging modality also showed potential for future targeted radiopharmaceutical therapies.
Researchers found lower levels of serotonin transporter and higher levels of amyloid-beta protein in brains of people with mild cognitive impairment, a potential target for treatments to slow or stop disease progression. Further research is needed to study the role of serotonin in disease progression.
Researchers have developed a novel PET radiotracer that enables early detection of inflammatory bowel disease (IBD) with high spatial and molecular specificity. The imaging tool targets the IBD biomarker IL12/23p40, providing detailed information for accurate diagnosis and treatment.
A study found that bone scans overstage prostate cancer at initial staging, leading to potential withholding of definitive therapy from patients. PSMA PET is more accurate than CT and bone scans for staging patients with prostate cancer.
Researchers used dynamic total-body PET scans to visualize immune T cell distribution in recovering patients. The study found increased concentrations of CD8+ T cells in the bone marrow of recovering COVID patients compared to healthy controls.
A new AI tool provides fully automated, easy-to-use evaluation of brain tumors using amino acid PET scans. The deep learning-based segmentation algorithm assesses treatment response with quality comparable to that of an experienced physician.
Researchers at Osaka University have developed a novel radioactive antibody that can diagnose and treat a deadly type of pancreatic cancer. The antibody targets glypican-1, a protein highly expressed in PDAC tumors, allowing for early detection and treatment with improved survival rates.
Researchers found a single dose of ADC therapy combined with lovastatin reduced tumor volume rates similar to multiple doses in preclinical settings. Immuno-PET scans also monitored HER2 tumor levels after treatment, offering real-time insights into therapy response and potential personalized cancer treatments.
Researchers at The Florey and Austin Health have discovered a way to detect Parkinson's disease 20-30 years before symptoms appear using a known biomarker called F-AV-133. PET scans show significant neuronal loss in three key brain regions, suggesting the biomarker is more sensitive than current methods.
A study of hospitalized adults with new-onset atrial fibrillation found that 1 in 3 patients experienced a recurrent episode of AF within a year. This rate is approximately 7 times higher than in matched control participants, suggesting that oral anticoagulation therapy may be warranted for these patients.
A new tau PET radiotracer, 18F-SNFT-1, demonstrates high sensitivity and specificity in identifying Alzheimer's disease. This improved tracer enables earlier diagnosis and potential therapeutic interventions.
A new imaging agent, 68Ga-ABY-025, can predict early metabolic response to HER2-targeted treatment in HER2-positive metastatic breast cancer patients. Whole-body PET/CT enables quantification of HER2 expression and predicts metabolic response, potentially sparing patients from unnecessary side effects.
An international team has decoded the TSPO protein to visualize neuroinflammation, revealing its relationship with microglial cells. The study's findings pave the way for optimizing observation of neuroinflammatory processes and re-reading previous studies.
A new blood-based test called p-tau217 has shown great promise in identifying Alzheimer's disease by stratifying patients into low, intermediate, and high-risk groups. The two-step workflow reduces the need for confirmatory testing in uncertain cases.
A new imaging technique, tau PET, has been shown to predict cognitive decline in Alzheimer's patients with greater accuracy than current methods. This breakthrough could lead to earlier diagnosis and treatment, improving patient outcomes.
PSMA PET imaging provides prognostic information on cancer recurrence risk before treatment, improving personalized treatments and guiding surgical plans. The tool outperforms current standard tests in predicting biochemical recurrence, a critical factor in determining cancer-specific mortality.
Researchers have discovered a novel copper protein binding site that shows promise for use in magnetic resonance imaging (MRI) contrast agents, potentially leading to clearer images and improved diagnoses. The new structure displayed highly effective levels of relaxivity, equal and superior to existing Gd(III) agents used in clinical MRI.
A new study investigated the use of positron emission tomography (PET) with radiotracer (18F)-Flortaucipir to detect chronic traumatic encephalopathy (CTE) in former professional American-style football players. The study found no significant differences in (18F)-FTP uptake between former players and age-matched male control participan...
A study at University of Turku found that reduced central thalamic nuclei activity is related to anesthesia-induced disconnectedness for propofol, dexmedetomidine, and sevoflurane. In contrast, S-ketamine was associated with increased left parietal cortex activity during disconnection.
Researchers developed a computational technique combining genomic and tau PET imaging data to identify four subtypes of Alzheimer's disease. The integrated approach also revealed top genes associated with each subtype. This personalized diagnostic technique has potential for broad utility across various diseases.
Henry VanBrocklin, a professor at the University of California, San Francisco, has been recognized for his decades-long research on novel radiopharmaceuticals and their applications in medical imaging. He is being honored with the prestigious Paul C. Aebersold Award for his contributions to nuclear medicine.
A new PET radiotracer called <sup> 18 </sup> F-Cholestify has been developed to visualize metabolic cholesterol clearance in the brain. The tracer successfully visualized brain cholesterol metabolism in rats, non-human primates, and humans, showing promising results for studying neurodegenerative diseases.
Mullani, a pioneer in positron emission tomography (PET) prototype development, has been recognized for his significant contributions to the field. He developed new innovations in PET designs and published the first validation of time-of-flight information in PET to improve image quality.
Researchers have developed a new PET model to quantify cardiac amyloidosis, allowing for more accurate diagnoses and monitoring. The study found that a two-tissue reversible compartment model is the best method for quantifying 18F-flutemetamol myocardial uptake.
A novel imaging agent has been developed to non-invasively detect pulmonary fibrosis in its early stages. The agent targets extracellular matrix fibers and has shown significant uptake in lungs with pulmonary fibrosis, matching histological results. This breakthrough could lead to earlier detection and better monitoring of the disease.
Researchers have made a significant finding in detecting brain tumors by exploiting folate receptors. Folate receptor expression is significantly higher in glioma tissue compared to adjacent healthy brain tissue, presenting a promising target for future treatments.
A Houston Methodist study found that COVID-19 variants and severity affect heart function, with microvascular involvement seen less often after nine months. The study recommends PET scans to check for microvascular dysfunction, which may be reversible.
Researchers confirm increased protein marker of inflammation in long COVID patients' brains, impacting depression and cognitive symptoms. CAMH study provides hope for new treatments using anti-inflammatory medications.
Researchers from the UCLA Jonsson Comprehensive Cancer Center are presenting findings on combination therapies for breast cancer and a potential new treatment for patients with recurrent glioma. A phase 3 study evaluating vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation is also be...
Researchers used a radiotracer to investigate AMPAR trafficking in patients with epilepsy, finding a positive correlation between cell surface AMPAR density and gamma activity. The study suggests that Hebbian and homeostatic plasticity differentially regulate brain function in epilepsy.
A recent meta-analysis shows that amino acid PET can accurately differentiate between recurrent brain metastases and treatment-related changes. This technology has the potential to reduce unnecessary invasive procedures and overtreatment in patients with cancer.